Tags : CV Risks

AstraZeneca’s Farxiga (dapagliflozin) Receives the US FDA’s Priority Review Voucher

Vartika Singh January 6, 2020

Shots: The Farxiga’s sNDA is based on P-III DAPA-HF trial involves assessing of Farxiga + SoC (10mg, qd) vs PBO in patients with heart failure and reduced ejection fraction (LVEF […]readmore

Tags : CV Risks

AstraZeneca’s Farxiga (dapagliflozin) Receives the US FDA’s Priority Review Voucher

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : CV Risks

AstraZeneca’s Farxiga (dapagliflozin) Receives the US FDA’s Priority Review Voucher

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company